M A N U S C R I P T A C C E P T E D ARTICLE IN PRESS

M A N U S C R I P T A C C E P T E D ARTICLE IN PRESS M A N U S C R I P T A C C E P T E D ARTICLE IN PRESS
For pseudomyxoma peritonei (PMP), survival depends on pathological grade and completeness of cytoreductive surgery. The aim of the study was to assess the ability of preoperative 18F-FDG PET to determine those 2 prognosis indicators.
MATERIAL AND METHODS:
In this prospective monocentric study, all patients presenting PMP were included. They underwent a preoperative 18F-FDG PET with a double radiological evaluation and an explorative laparotomy with the objective of optimal cytoreduction followed by a hyperthermic intra-operative intraperitoneal chemotherapy (HIPEC). Patients with non resectable disease underwent debulking surgery without HIPEC. The Completeness of Cytoreduction was assessed by CCscore.
RESULTS:
Thirty-four patients were included. PET scanning was positive for 19 patients with grade II (hybrid form) or III (peritoneal mucinous cystadenocarcinoma) and for 2 patients with grade I (disseminated peritoneal adenomucinosis), and negative for 3 patients with grade II -III and for 10 patients with grade I. PET scanning was positive for 6 patients with CCscore 2 -3 and for 16 patients with CCscore 0, and negative for 2 patients with CCscore 2 -3 and for 10 patients with CCscore 0. The 18F-FDG PET interpretation distinguished 2 patients groups (grade I and grade II -III) with a sensibility of 90% and a specificity of 77%. Moreover, probability of complete cytoreduction when PET was negative was over 80%. Pseudomyxoma peritonei (PMP) is an uncommon disease affecting 1 per million population with an estimated incidence of 2 cases per 10 000 laparotomies (1). In 1884, Werth (2) reported the first case of PMP, describing gelatinous material from an ovarian cyst in the peritoneal cavity. Developments in immunohistochemical techniques and genetic analysis now suggest the origin of PMP is the appendix (3) (4) in the majority of cases. As a result of the proliferation of mucin there is an increase in intra-abdominal pressure. This phenomenon causes intestinal obstruction and often leads to the patient's death. As suggested by Sugarbaker (5) , the current standard of care with curative intent should be the combination of cytoreductive surgery (CRS) with hyperthermic intra-operative intraperitoneal chemotherapy (HIPEC).
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A number of specialized teams involved in the management of PMP use three pathological grades for classification (6) (7), grade I or « disseminated peritoneal adenomucinosis » (DPAM), grade III or « peritoneal mucinous cystadenocarcinoma » (PMCA) and grade II or intermediate hybrid form. For patients treated by CRS combined with HIPEC, the 5 year survival rate varies from 74 to 100 % for grade I, and from 30 to 54 % for grade II and III with less favourable prognosis for PMCA (8) (9) . Pathological grades, prior surgical score (PSS) (10) and residual disease measure by Completeness of Cytoreduction score (CCscore) (10) have been found to be the main prognostic factors in several prospective studies (7) (11) (12) . It remains difficult to predict preoperatively the completeness of cytoreduction which is dependent on pathological grade and disease extent (12) . 
Surgery
All patients underwent an explorative laparotomy, beginning with a complete intraperitoneal exploration and with the evaluation of disease extent using Gilly's peritoneal carcinomatosis staging (16)(17), and Sugarbaker's Peritoneal Cancer Index (10). The surgical goal was to obtain a complete cytoreduction, with residual disease nodules no greater than 5 mm, followed by hyperthermic intraperitoneal chemotherapy (HIPEC) at 42 °C for 90 minutes, using mitomycin C (0.5 mg/kg) and cisplatin (0.7 mg/kg). Peritonectomy procedures and surgical resection were performed according to Sugarbaker (18) . Patients with non resectable disease underwent debulking surgery. Peritoneal disease was considered non resectable in the presence of extensive small bowel or mesenteric involvement, extensive pelvic disease or severe co-morbidity precluding extensive surgery. The residual disease was assessed by the 
M A N U S C R I P T A C C E P T E D ARTICLE IN PRESS
12
Their age and co-morbidity prevented complete cytoreduction. Preoperative 18F-FDG PET was negative for 10 out of 26 patients with complete cytoreduction, and positive for 6 patients out of 8 with incomplete cytoreduction. When preoperative PET scanning was negative the probability of complete cytoreduction was 0.83. The probability of incomplete cytoreduction was 0.27 when PET scanning was positive. Predictive positive value of preoperative 18F-FDG PET to assess completeness of cytoreduction was 27%, predictive negative value was 83%, with 75% sensitivity and 38% specificity. According to Yule's Q coefficient, the strength of relationship between uptake of 18F-FDG and the CC score was significant (0.3).
Youden's index was 0.13. (12) (19) . Surgical history represented by the Prior Surgical Score (PSS) (10), pathological grade (3) and completeness of cytoreduction (10) have all been reported as important prognostic factors. According to pathologicalal grade as described by Ronnett, 2 broad groups exist: patients with DPAM who have 84 % 5 years survival and patients with PMCA or hybrid form with a 7 and 38 % 5 years survival, respectively (7) (6) .
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CT (Computed Tomography) features such as presence of an appendiceal mucocele (20) , low attenuation ascites, visceral scalloping, septae in mucinous material, calcification and omental cake may all suggest the diagnosis of PMP (21) . Disease in dependent areas of the peritoneal cavity is described as the redistribution phenomenon (22) . CT scan features of DPAM are typically calcification, and of PMCA, omental cake or lymph nodes (23) . Absence of bowel obstruction with no tumor deposits on the jejunum and proximal ileum (24) and small volume disease on pre-operative CT scan (21) all suggest that complete cytoreduction may be possible.
18F-FDG PET is reported to have a sensitivity varying from 35.5 to 88% for detection of peritoneal carcinomatosis depending on origin (13) (25) (14). However, CT scan appears to have higher sensitivity for preoperative staging of peritoneal carcinomatosis (26), compared to PET which underestimates the extent of lesions, especially for nodes less than 5mm (13) (14) (15) (27) . Preoperative chemotherapy is another potential confounding factor, but no patient received preoperative systemic chemotherapy in the three months preceding 18F-FDG PET in our study. Therefore it is unlikely that our findings were affected by this.
The purpose of this study was to assess the ability of 18F-FDG PET to aid preoperative assessment of patients with PMP by identifying patients in whom complete cytoreduction was likely to be achieved. PET scanning seems to be effective in differentiating between patients who have absence of uptake of 18F-FDG and are likely to have DPAM, and those who have uptake of 18F-FDG with a probable PMCA or hybrid form. 18F-FDG PET may also be effective in the pre-operative evaluation of completeness of cytoreduction. 
